BC Week In Review | May 2, 2016
Company News

Cao Pharmaceuticals, NanoMaterials deal

Cao granted NanoMaterials’ NMT Pharmaceuticals Pte. Ltd. subsidiary exclusive, worldwide rights to develop and commercialize cancer candidate CZ-48 . The analog of camptothecin, a topoisomerase ( TOP1 ) inhibitor, was co-developed by Cao and NMT and is in...
Items per page:
1 - 1 of 1